Study on Bevacizumab for Eye Disease
Author Information
Author(s): Praveen J Patel, Catey Bunce, Adnan Tufail
Primary Institution: Moorfields Eye Hospital
Hypothesis
Can intravitreal bevacizumab injections improve visual acuity in patients with choroidal neovascularisation due to age-related macular degeneration compared to standard therapy?
Conclusion
The study aims to determine if bevacizumab is more effective than standard treatments for improving vision in patients with age-related macular degeneration.
Supporting Evidence
- This trial is the first to use visual gain as the primary outcome measure.
- Bevacizumab is widely used for treating age-related macular degeneration despite limited evidence.
- The study includes a diverse range of treatment options for comparison.
Takeaway
This study is testing if a common eye injection can help people see better compared to other treatments.
Methodology
Double-masked, randomised controlled trial comparing intravitreal bevacizumab injections to standard therapy.
Potential Biases
Potential bias due to the off-label use of bevacizumab and the selection of control treatments based on funding.
Limitations
The study may not include all potential treatment options available at the time of recruitment.
Participant Demographics
Patients over 50 years with neovascular age-related macular degeneration.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website